A new look at evaluating MTD designs in cancer research (Q2431683): Difference between revisions
From MaRDI portal
Set profile property. |
ReferenceBot (talk | contribs) Changed an Item |
||
| (One intermediate revision by one other user not shown) | |||
| Property / full work available at URL | |||
| Property / full work available at URL: https://doi.org/10.1080/15598608.2009.10411930 / rank | |||
Normal rank | |||
| Property / OpenAlex ID | |||
| Property / OpenAlex ID: W2059268290 / rank | |||
Normal rank | |||
| Property / cites work | |||
| Property / cites work: A Random Walk Rule for Phase I Clinical Trials / rank | |||
Normal rank | |||
| Property / cites work | |||
| Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank | |||
Normal rank | |||
| Property / cites work | |||
| Property / cites work: Design and Analysis of Phase I Clinical Trials / rank | |||
Normal rank | |||
Latest revision as of 23:02, 3 July 2024
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A new look at evaluating MTD designs in cancer research |
scientific article |
Statements
A new look at evaluating MTD designs in cancer research (English)
0 references
18 April 2011
0 references
maximum tolerated dose
0 references
probit regression
0 references
dose escalation designs
0 references
tolerance distribution
0 references
